APC to commercialize new bacterial strain for metabolic and mental health
date:Dec 21, 2020
B. longum species from initial laboratory studies through preclinical studies to a human intervention study.

This strain is a great example of a success story, showing the identification of a novel strain and a putative mechanism of action using laboratory studies. Within APC, we have adopted this bug-to-drug screening platform for the identification of the most promising bacterial strains, which are then more likely to yield a positive health effect in preclinical and human studies.

Earlier
7/9 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/25 03:09